Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral blood progenitor cell transplantation: economic issues

G C Yee1

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Florida Health Science Center, Gainesville 32610, USA.

Pharmacotherapy
|February 24, 1998
PubMed
Summary

High-dose chemotherapy with autologous hematopoietic stem cell rescue offers survival benefits but faces cost-effectiveness concerns. Strategies are emerging to reduce its high price, improving accessibility for cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

Clinical pharmacology and therapeutics·2006
Same author

Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells.

Bone marrow transplantation·2001
Same author

Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong.

Alimentary pharmacology & therapeutics·2001
Same author

Pharmacoeconomics of biotechnology drugs (2).

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·1998
Same author

The clinical and economic rationale for peripheral blood progenitor cell transplantation. Introduction.

Pharmacotherapy·1998
Same author

Cost-utility analysis of taxane therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998

Area of Science:

  • Oncology
  • Health Economics

Background:

  • High-dose chemotherapy with autologous hematopoietic stem cell rescue is a costly cancer treatment.
  • While offering improved long-term survival, its economic viability is increasingly scrutinized.
  • The cost-effectiveness is closely tied to the survival advantage over standard-dose chemotherapy.

Purpose of the Study:

  • To evaluate the cost-effectiveness of high-dose chemotherapy with autologous hematopoietic stem cell rescue.
  • To review economic analyses concerning this treatment modality, particularly in breast cancer.
  • To identify strategies aimed at reducing the overall cost of this intensive therapy.

Main Methods:

  • Economic analyses and cost-effectiveness ratio assessments were reviewed.
  • Comparisons were made between high-dose and standard-dose chemotherapy outcomes.

Related Experiment Videos

  • Investigated cost-reduction strategies were identified.

    • Main Results:

    • The cost-effectiveness ratio for high-dose chemotherapy in breast cancer treatment is comparable to other accepted medical interventions.
    • Survival benefit is the primary determinant of its cost-effectiveness.
    • Various centers are exploring methods to decrease therapy expenses.

    Conclusions:

    • High-dose chemotherapy with autologous hematopoietic stem cell rescue presents a complex cost-benefit profile.
    • Further research into cost-reduction strategies is crucial for wider application.
    • Optimizing treatment delivery and resource utilization can enhance economic feasibility.